Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH management, high unmet need remains for drugs that offer improved survival, long-term efficacy, and better QOL. According to physicians interviewed by DRG, there is scope for novel therapies offering patients a better prognosis. Based on quantified physician perception of current therapies, we discuss the attractiveness of drug attributes and the implications for PAH drug development. Understanding the influence of key efficacy, safety/tolerability, and nonclinical attributes on physician prescribing behavior is important to achieve commercial success in this competitive landscape. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for PAH.


  • What are the key treatment drivers and goals for PAH? How do the current therapies perform on these goals?
  • What attributes drive decision-making for managing PAH patients, which have limited impact, and which are hidden opportunities?
  • Based on a conjoint analysis and Target Product Profile (TPP) simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists and pulmonologists for a hypothetical PAH drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 61 U.S. and 32 European cardiologists and pulmonologists fielded in July 2018.

Key companies: Actelion, Bayer, Gilead, GlaxoSmithkline, Pfizer, and United Therapeutics.

Key drugs: Adempas, Uptravi, Letairis, Opsumit, Adcirca, Orenitram, and sildenafil.

Table of contents

  • Detailed, Expanded Analysis ( US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Convenience of Administration
        • Safety and Tolerability
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Pulmonary Arterial Hypertension
      • Key Findings: Unmet Need in Pulmonary Arterial Hypertension and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Pulmonary Arterial Hypertension Market and Emerging Therapy Insights
        • Opportunity: A Novel Oral Agent with Greater Reductions in Mortality Rate
        • Opportunity: A New Oral PAH Therapy with Greater Reductions in Incidence of Clinical Worsening
        • Opportunity: A Novel Therapy with Greater Improvements in NYHA/WHO Functional Class and Improvements in Exercise Capacity, with Associated Improvements in QOL
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Pulmonary Arterial Hypertension Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
        • Scenario 3
    • Appendix
      • Bibliography

Author(s): Pallavi Malik, M.Sc

Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.  

Related Reports

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of dr...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details